News Synchron to begin trials of world's first paralysis brain im... US developer of neuromodulation devices, Synchron, has raised $10 million to begin human trials of its world's first endovascular neural interface technology, Stentrode, to help paralysed p
News GSK boosts anti-infectives pipeline with Scynexis antifungal Last year, GSK said it was planning to invest a cool £1 billion in infectious d
R&D Sponsored Trials and tribulations of drug development What does it take to establish new treatments for rare diseases?
